A new study suggests that the surge in pandemic-fueled drinking caused a sharp and continuing rise in fatal liver disease, ...

Sarepta has issued a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl) following a second reported case of acute liver failure resulting in death.

Follow-up reached a median 5.5 years overall. Adverse liver outcomes in question counted cirrhosis, decompensation, ...

Their results reveal a significantly elevated risk of death among MASLD patients from various diseases, not just liver-related issues. Overall, the mortality rate nearly doubled compared to the ...

Alcohol-related liver disease deaths are increasing—and they're rising faster in some groups, including women, young adults ...

Fatty liver disease by itself is unlikely to cause sudden death. However, it can cause complications that can potentially lead to death. The liver is the body’s primary detoxifying organ.

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Alcohol-related liver disease deaths are increasing rapidly among women and young adults, according to new research.

Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy ...

Alcohol-related liver disease deaths are increasing rapidly among women and young adults, according to new research.